Fujitsu announced two initiatives to further digital transformation in clinical trials: an integrated clinical trial platform with Paradigm Health and a GenAI-enabled document automation workflow named Patient-centric Clinical Trials.
OM122935
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Fujitsu advances the digital transformation of clinical trials
These are Omdia driven recommendations based on content that is both similar, and has been frequently visited by other users in combination with the content you are currently viewing.
Omdia Recommends
These are Omdia driven recommendations based on content that is both similar, and has been frequently visited by other users in combination with the content you are currently viewing.
AI, Analytics, and Cloud Computing Are Transforming Clinical Trials
Report / 26 Sep 2024 / Andrew Brosnan
The latest wave of digital transformation to hit clinical trials is here, and sponsors are looking to AI, clinical data analytics, and cloud computing to bring innovation to the way clinical trials are designed, planned, and executed.
UPGRADE
An error occured. Please try again later
You are now following this Analyst
You unfollowed this Analyst
Become A Client
Find out more about our full suite of products and solutions.
Become A ClientYou must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ask An Analyst
These are Omdia driven recommendations based on content that is both similar, and has been frequently visited by other users in combination with the content you are currently viewing.
Omdia Recommends
These are Omdia driven recommendations based on content that is both similar, and has been frequently visited by other users in combination with the content you are currently viewing.
Thank you
Our expert analysts will review your question and the Ask an Analyst team will get back to you. We aim to respond within 24 hours, but we’re often quicker.
Ask an Analyst
Our team of experts are here to answer your questions. From advice on market trends to a query on research point, and everything in between, we want to hear from you.
Ask an analyst is available as part of a subscription. If you'd like access, contact us today.